BPA Biosante Pharmaceuticals

BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that Stephen M. Simes, the Company�s president and chief executive officer, will present a corporate and clinical overview of the Company at the Rodman & Renshaw 8th Annual Healthcare Conference, taking place at the New York Palace Hotel in New York City, on November 6-8, 2006. Mr. Simes� presentation is scheduled for November 7, 2006 at 3:55 p.m. EST. A live audio webcast of BioSante�s presentation may be accessed at http://www.biosantepharma.com/investors/events.html with a replay available at the same link for 90 days. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel� (transdermal estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel� (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was submitted to the FDA in the first quarter 2006. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma Inc. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at: www.biosantepharma.com. BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that Stephen M. Simes, the Company's president and chief executive officer, will present a corporate and clinical overview of the Company at the Rodman & Renshaw 8th Annual Healthcare Conference, taking place at the New York Palace Hotel in New York City, on November 6-8, 2006. Mr. Simes' presentation is scheduled for November 7, 2006 at 3:55 p.m. EST. A live audio webcast of BioSante's presentation may be accessed at http://www.biosantepharma.com/investors/events.html with a replay available at the same link for 90 days. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(R) (transdermal estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(R) (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was submitted to the FDA in the first quarter 2006. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma Inc. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at: www.biosantepharma.com.